Cancer therapy with vaccination using HLA-A24-restricted peptide from URLC10:a phase I study in patient with unresectable esophageal cancer
Phase 1
- Conditions
- unresectable esophageal cancer
- Registration Number
- JPRN-UMIN000000955
- Lead Sponsor
- Institute of Medical Science The University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
pregnancy uncontroled infection uncontroled cerebral metastasis etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method